Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML.

Blood Adv · 2025 · PMC11787451 · PMID 39293081

Europe PMC DOI

hedged sentence

0.1500

closest p · 3.0× alpha

0.1500

boldest claim

The sentences

did not reach statistical significanceP = .15not close (p > 0.1)

Furthermore, we also noticed a trend toward prolonged OS, even though this difference did not reach statistical significance (15.8 months [95% CI, 10.6 to NE] vs 10.5 months [95% CI, 6.8-19.6], respectively; P = .15).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.